Why Lexicon Pharma's Stock Is Surging Higher Today

Lexicon Pharmaceuticals LXRX shares are trading sharply higher after the company announced it received FDA regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission.

Lexicon is a biopharmaceutical company developing medicines that transform patients' lives. The company commercializes and develops drugs and drug candidates.

Lexicon's stock was trading higher by 102% to $7.92 at the time of publciaiton.